극단적 과매도 속에서 시작된 임상 기대감의 반등

Regeneron-backed Parabilis rises ahead of trial data for lead asset

ENTRY PRICE$25.82Entry reference price

AI PREDICTION+4.5%Predicted upside

VERIFIED RESULT11.2%11.2% up

PREDICTION GAP+6.7%pGap vs. actual result

CONFIDENCE78AI analysis confidence

CATALYST SUMMARY

What was the news?

View Original ↗

Parabilis, backed by Regeneron, is on an upward trend ahead of the release of clinical data for its lead asset.

INITIAL SCENARIO

AI's Initial Call

Entry Rationale

Attempting a rebound based on the support line ($22.66) from an extreme oversold range, buying may be considered.

Target/Stop Scenario

If it holds above the support level ($22.66) without breaking, I will aim for scaling out profits in stages up to the resistance level of $42.32. Conversely, if it falls below the support level of $22.66 and the defense collapses, I will cut losses immediately.

Take-profit reference$42.32

Stop-loss reference$22.66

TECHNICAL BASELINE

Market Data at Analysis Time

RSI13.7

Vs. Average Volume0.8×

Recent Change-21.1%

MA20$30.1MA60$34.8

RSI(14) is in an extreme oversold state at 13.7, with trading volume at 0.80x the 20-day average and the 7-day volatility (rate of change) recording -21.1%.

AI LEARNING NOTE

Reviewing Prediction vs. Actual Result

Exceeding the predicted return rate of 4.5% with an actual increase of 11.2%, the stock received an OVERHIT judgment. Based on the extreme oversold RSI(14) of 13.7 at entry time and the support line at $22.66, a rebound was anticipated, but expectations of the upcoming clinical data announcement acted more strongly than anticipated, creating a strong upward trend that exceeded the target.

What to Watch in the Next Analysis

극단적인 과매도와 주요 지지선에서의 반등 시도라는 조건이 겹칠 때는 예상보다 강한 탄력이 붙을 수 있음을 확인했다. 향후 유사한 과매도 국면에서는 목표가 도달 이후의 추가 상승 여력(모멘텀 지속성)을 열어두는 유연한 대응 전략을 적용해야겠다.

V13 VERIFICATION

Chart Verification

V13 Worker auto-verified

Initial ChartAt Analysis · 2026-10-30

$25.82

Verification ChartVerification · 2026-10-30 08:32:14

11.2%

Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.